Adia Med, Inc. (ADIA) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Adia Med, Inc. (ADIA) stock forecast summary
Our AI scores Adia Med, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Adia Med, Inc. is a small-cap company with a market capitalization of $9M. It ranks number 19 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For ADIA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 17.0%, measured on 94 forecast dates between 2026-03-31 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 137 forecast dates between 2026-03-31 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ADIA included.
ADIA price chart and AI forecast
How ADIA ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Adia Med, Inc. (ADIA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | ADIA | Rank |
|---|---|---|
| Market Cap | $9M | 19/28 |
Financial Health
| Metric | ADIA | Rank |
|---|---|---|
| Current Ratio | 0.32x | 22/25 |
| Working Capital | -$710K | 19/25 |
Dividend & Shareholder Information
| Metric | ADIA | Rank |
|---|---|---|
| Shares Outstanding | 94M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $340K | |
| Cash & Short-term Investments | $130K | |
| Accounts Receivable | $40K | |
| Total Liabilities | $1M | |
| Short-term Debt | $1M |
ADIA quarterly financials and insider trading
Adia Med, Inc. (ADIA) industry peers
Companies classified under the same SEC industry code as Adia Med, Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ADIA Adia Med, Inc. | $9M | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where ADIA sits on the market map
Adia Med, Inc. (ADIA) stock news
Loading...
Adia Med, Inc. (ADIA) stock forecast FAQ
What is the Adia Med, Inc. (ADIA) stock forecast?
Our AI scores Adia Med, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Adia Med, Inc. stock predictions?
For ADIA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 17.0%, measured on 94 forecast dates between 2026-03-31 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 137 forecast dates between 2026-03-31 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Adia Med, Inc. forecasts updated?
Adia Med, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Adia Med, Inc.'s industry peers?
30 issuers in our coverage, ADIA included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.